Tovorafenib (DAY101)

RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

Also known as TAK-580

Manufacturer: Day One Biopharmaceuticals
Regulatory submission: Not announced
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

148 evidence topics · 64 sources

Current treatment options and standard of care82 evidence topics · 42 sources
Place in treatment, anticipated use, and care setting9 evidence topics · 12 sources
Heterogeneity of treatment effect13 evidence topics · 15 sources
Care management intervention strategies14 evidence topics · 18 sources
Other product development or post-marketing obligations required by the FDA10 evidence topics · 7 sources
Ongoing post-approval monitoring5 evidence topics · 4 sources
Expected outcomes of therapy15 evidence topics · 15 sources